Imaging Patients With Kidney Disease: How Do We Approach Contrast-Related Toxicity?

The approach to imaging patients with kidney disease with iodinated radiocontrast and gadolinium-based contrast has changed dramatically in recent times. The complications of these contrast agents, radiocontrast nephropathy and nephrogenic systemic fibrosis, respectively, underlie the changes in the imaging practice used in these patients. Rather than to completely avoid the use of these contrast agents, one must remain judicious in the choice of imaging modality in this group of patients. A prudent approach would be to (1) identify patients at high risk to develop contrast-related complications, (2) use noncontrast-based imaging techniques in these patients, as long as they are suitably diagnostic and safe and (3) if the risk:benefit ratio of the imaging information favors a contrast-based study, then appropriate prophylactic steps and use of contrast agents with the lowest risk of complication should be used after obtaining informed consent. This will allow one to maximize the diagnostic efficiency while also limiting the adverse effects.

[1]  Michael Weber,et al.  Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease. , 2010, European journal of radiology.

[2]  P. Kalra,et al.  Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[3]  Diego R. Martín,et al.  Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast‐enhanced MRI protocols , 2010, Journal of magnetic resonance imaging : JMRI.

[4]  B. Taouli,et al.  Diffusion-weighted MR imaging of the liver. , 2010, Radiology.

[5]  J. Kline,et al.  Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[6]  Diego R. Martín,et al.  Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities. , 2009, Radiology.

[7]  Peter Caravan,et al.  Primer on gadolinium chemistry , 2009, Journal of magnetic resonance imaging : JMRI.

[8]  M. Prince,et al.  Renal artery stenosis: imaging options, pitfalls, and concerns. , 2009, Progress in cardiovascular diseases.

[9]  S. Sauk,et al.  Ten-Year Experience With Nephrogenic Systemic Fibrosis: Case-Control Analysis of Risk Factors , 2009, Journal of computer assisted tomography.

[10]  H. Thomsen,et al.  Nephrogenic systemic fibrosis and contrast medium-induced nephropathy: a choice between the devil and the deep blue sea for patients with reduced renal function? , 2009, Acta radiologica.

[11]  M. Perazella Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm , 2009, Current opinion in nephrology and hypertension.

[12]  M. Prince,et al.  Nephrogenic systemic fibrosis and its impact on abdominal imaging. , 2009, Radiographics : a review publication of the Radiological Society of North America, Inc.

[13]  Stephanie R Wilson,et al.  Contrast-enhanced ultrasound: what is the evidence and what are the obstacles? , 2009, AJR. American journal of roentgenology.

[14]  Marino Labinaz,et al.  Contrast-induced nephropathy and long-term adverse events: cause and effect? , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[15]  Perazella Ma Radiocontrast-induced nephropathy: an update. , 2009 .

[16]  Paula M Jacobs,et al.  Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? , 2009, Kidney international.

[17]  S. Lai,et al.  Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases. , 2009, Radiology.

[18]  G. Wilson,et al.  Non-contrast-enhanced MR imaging of renal artery stenosis at 1.5 tesla. , 2009, Magnetic resonance imaging clinics of North America.

[19]  M. Perazella,et al.  Current status of gadolinium toxicity in patients with kidney disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[20]  Harold I Feldman,et al.  Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  M. Perazella Radiocontrast-induced nephropathy: an update. , 2009, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

[22]  M. Perazella,et al.  Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  Martin R Prince,et al.  Incidence of nephrogenic systemic fibrosis at two large medical centers. , 2008, Radiology.

[24]  M. Fine,et al.  Incidence and outcomes of contrast-induced AKI following computed tomography. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[25]  M. Mack,et al.  Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[26]  P. Patel,et al.  Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  D. Broome,et al.  Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. , 2008, European journal of radiology.

[28]  M. Perazella,et al.  How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease? , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[29]  R. Reilly Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[30]  H. Hussain,et al.  Nephrogenic systemic fibrosis: a report of 29 cases. , 2008, AJR. American journal of roentgenology.

[31]  J. Topf,et al.  Nephrogenic Fibrosing Dermopathy , 2008, TheScientificWorldJournal.

[32]  H. Thomsen,et al.  High Prevalence of Nephrogenic Systemic Fibrosis in Chronic Renal Failure Patients Exposed to Gadodiamide, a Gadolinium-Containing Magnetic Resonance Contrast Agent , 2008, Investigative radiology.

[33]  S. Punwani,et al.  NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Non‐Gadolinium Options for the Imaging of CKD/ESRD Patients , 2008, Seminars in dialysis.

[34]  R. Woolson,et al.  Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  D. Tudorascu,et al.  Nephrogenic systemic fibrosis: Center case review , 2007, Journal of magnetic resonance imaging : JMRI.

[36]  L. Skov,et al.  Case-control study of gadodiamide-related nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  A. Jardine,et al.  Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. , 2007, Radiology.

[38]  W. Eubank,et al.  Steady‐state free precession MRA of the renal arteries: Breath‐hold and navigator‐gated techniques vs. CE‐MRA , 2007, Journal of magnetic resonance imaging : JMRI.

[39]  G. Scott,et al.  Nephrogenic systemic fibrosis: a clinicopathologic study of six cases. , 2007, Journal of the American Academy of Dermatology.

[40]  A. Djamali,et al.  Nephrogenic systemic fibrosis: risk factors and incidence estimation. , 2007, Radiology.

[41]  S. Cowper,et al.  Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[42]  Gerald A Kirk,et al.  Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. , 2007, AJR. American journal of roentgenology.

[43]  V. Runge,et al.  Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan) , 2007, Investigative radiology.

[44]  J. Zic,et al.  Gadolinium deposition in nephrogenic fibrosing dermopathy. , 2007, Journal of the American Academy of Dermatology.

[45]  S. Cowper,et al.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.

[46]  D. Elston Community-acquired methicillin-resistant Staphylococcus aureus. , 2007, Journal of the American Academy of Dermatology.

[47]  S. Cowper,et al.  Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.

[48]  R. Bucala,et al.  Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy) , 2006, Current opinion in rheumatology.

[49]  T. Grobner Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[50]  B. Krumme,et al.  Renal Doppler Sonography – Update in Clinical Nephrology , 2006, Nephron Clinical Practice.

[51]  Kirk N. Garratt,et al.  Incidence and Prognostic Importance of Acute Renal Failure After Percutaneous Coronary Intervention , 2002, Circulation.

[52]  G. Dangas,et al.  The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. , 2000, Journal of the American College of Cardiology.

[53]  P. Leboit,et al.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.

[54]  H. Thomsen,et al.  Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. , 1998, Academic radiology.

[55]  W. O’Neill,et al.  Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. , 1997, The American journal of medicine.

[56]  C. Viscoli,et al.  The effect of acute renal failure on mortality. A cohort analysis. , 1996, JAMA.